Document Detail

Unbiased estimates of long-term net survival of haematological malignancy patients detailed by major subtypes in France.
MedLine Citation:
PMID:  23034773     Owner:  NLM     Status:  Publisher    
Long-term population-based survival data detailed by cancer subtype are important to measure the overall outcomes of malignancy managements. We provide net survival estimates at 1, 3, 5, and 10 years post-diagnosis on 37,549 haematological malignancy (HM) patients over 15 years old diagnosed between 1989 and 2004 and actively followed until 2008 by French population-based cancer registries. These are, to our knowledge, the first unbiased estimates of ten-year net survival in HMs detailed by subtypes. HMs were classified according to the International Classification of Diseases-Oncology-3. Net survival was estimated with the unbiased Pohar-Perme method. The results are reported by sex and age-classes. The changes of these indicators by periods of diagnosis were tabulated and the trends of the net mortality rates over time since diagnosis graphed. Five and 10-year age-standardized net survivals after HMs varied widely from 81% and 76% for classic Hodgkin lymphoma (CHL) to 18% and 14% for acute myeloid leukaemia (AML). Even in HMs with the most favourable prognoses, the net survival decreased between 5 and 10 years post-diagnosis. Women had better prognoses than men and age at diagnosis was an unfavourable prognostic factor for most HMs. In patients less than 55 years old, the net mortality rate decreased to null values five years post-diagnosis in AML and ten years post-diagnosis in CHL, precursor non-Hodgkin lymphoma, chronic myelogenous leukaemia, diffuse large B-cell lymphoma, and follicular lymphoma. The prognoses improved for various HMs over the study period. The obtained unbiased indicators are important to evaluate national cancer plans.
Alain Monnereau; Xavier Troussard; Aurélien Belot; Anne-Valérie Guizard; Anne-Sophie Woronoff; Simona Bara; Bénédicte Lapôtre-Ledoux; Jean Iwaz; Brigitte Tretarre; Marc Maynadié;
Related Documents :
24039273 - Estimation of progression-free survival for all treated patients in the randomized disc...
23747773 - Timing of hemoconcentration during treatment of acute decompensated heart failure and s...
21989183 - Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-3
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  -     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 UICC.
Registre des Hémopathies Malignes de la Gironde, Institut Bergonié, F-33076, Bordeaux, France; Centre INSERM U897, CIC-EC7, Centre d'Investigation Clinique - Epidémiologie Clinique, F-33076, Bordeaux, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prediction and control of number of cells in microdroplets by stochastic modeling.
Next Document:  The Impact of Incarceration on Women's Mental Health: Responses From Women in a Maximum-Security Pri...